Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Ann Hsing
Institution
NCI, DCEG, HREB
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0223
Initial CDAS Request Approval
Jul 1, 2006
Title
Prostate Cancer Other Factors-NSAIDs
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) may protect against prostate cancer by inducing apoptosis, inhibiting tumor cell proliferation and invasion, and reducing angiogenesis, in part through inhibition of the cyclooxygenase-2 enzyme. Although most epidemiologic studies suggest that NSAID use is inversely associated with prostate cancer, the magnitude and specificity of this association remain unclear. We examined aspirin and ibuprofen use in relation to prostate cancer risk among 29,356 men ages 55 to 74 who were initially screened for prostate cancer from 1993 to 2001 in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Men were followed from their first screening exam until September 30, 2002, during which 1,338 cases of prostate cancer were identified. Data on NSAID use were collected at baseline by a self-administered questionnaire.
Aims

To determine whether use of NSAIDs is associated with reduced risk of prostate cancer in a large prospective study.

Collaborators

David Chia (UCLA)
Gerald Andriole (Washington University)
Kim Danforth
Timothy Church (University of Minnesota)

Related Publications